Novavax, Inc. (NASDAQ:NVAX) & Johnson & Johnson (NYSE:JNJ) Stocks in the Spotlight
- Author: Zachary Reyes May 23, 2017,
May 23, 2017, 8:53
Analysts expect that Novavax, Inc. will post ($0.62) EPS for the current year. This estimate is provided by 5700 analysts. (NASDAQ:NVAX) a mean recommendation of 2.70.
Over the last 5 years, Novavax, Inc. has averaged a -43.40% YoY EPS growth rate and a 0.90% revenue growth rate. Looking ahead to earnings forecasts, for the running fiscal period, Wall Street analysts have anticipated that the company will report 0.33 earnings per share. The Return on Equity (ROE) value stands at -787.4%. The company had revenue of $5.68 million during the quarter, compared to the consensus estimate of $6.17 million. The company's revenue was up 34.6% on a year-over-year basis.
Novavax, Inc. (NVAX) closed its previous trading session at $1.08 with the gain of 4.85%. Ladenburg Thalmann Financial Services reiterated a "neutral" rating on shares of Novavax in a research report on Wednesday, March 1st.
Novavax, Inc. (NVAX) has a market capitalization of 308.05 Million which suggests the company is a huge company further suggesting that the shares of Novavax, Inc.
Stock is now moving with a negative distance from the 200 day simple moving average of approximately -54.41%, and has a poor year to date (YTD) performance of -17.46% which means the stock is constantly subtracting to its value from the previous fiscal year end price. The Volatility was noted at 1.59% in recent month and it observed Weekly Volatility of 0.94%.
09/16/2016 - Novavax, Inc. was downgraded to "neutral" by analysts at Citigroup. "(NVAX) Expected to Announce Quarterly Sales of $5.81 Million" was originally posted by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & worldwide trademark & copyright legislation.
The stock subtracted in the prior trading session by -4.59%, closing at the stock price of $1.04. Over the past week, shares are 4.00%. Novavax has a 52 week low of $0.73 and a 52 week high of $8.49. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. The stock was purchased at an average cost of $0.84 per share, for a total transaction of $42,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders bought 105,000 shares of company stock worth $90,800. NY now owns 203,996 shares of the biopharmaceutical company's stock worth $257,000 after buying an additional 5,704 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Novavax during the first quarter valued at about $157,000. HighTower Advisors LLC boosted its position in Novavax by 3.8% in the first quarter. Leading up to this report, we have seen a 24.1% rise in the stock price over the last 30 days and a -36.42% decline over the past 3 months.
The market experts are predicting a 67.31% rally, based on the high target price ($26) for CONSOL Energy Inc. shares that is likely to be hit in the 52 weeks. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company's stock valued at $213,000 after buying an additional 10,965 shares in the last quarter.
Shares outstanding are recorded as 261.60 M and total shares floated are 261.60 M. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 1.50. Finally, Renaissance Technologies LLC acquired a new stake in shares of Novavax during the fourth quarter worth approximately $544,000. KCG Holdings Inc. now owns 178,797 shares of the biopharmaceutical company's stock valued at $229,000 after buying an additional 110,292 shares in the last quarter.